TCT

SAN DIEGO — A final analysis of 24-month results from the SURTAVI trial confirmed interim findings that transcatheter aortic valve replacement with a self-expanding bioprosthesis had similar outcomes vs. surgical AVR in patients at intermediate risk for surgery.

SAN DIEGO — Two trials have demonstrated the noninferiority of a new drug-coated balloon with a novel excipient when compared with a currently available DCB for in-stent restenosis and a second-generation drug-eluting stent in small-vessel disease.

SAN DIEGO — Despite the evidence for the safety, efficacy and cost-effectiveness of drug-coated balloons for peripheral interventions, their use in clinical practice has become overshadowed by fiscal concerns, according to a presentation at TCT 2018.

SAN DIEGO — Long-term data from the CvLPRIT trial support complete revascularization compared with PCI of the infarct-related artery only.

SAN DIEGO — A history of data backs the use of surgery in patients with common femoral artery lesions, but as more studies emerge, endovascular therapy also is carving out a space, according to two speakers at TCT 2018. George S. Chrysant, MD, from the department of cardiology at INTEGRIS Heart Hospital in Oklahoma City, and Virendra I. Patel, MD, from the department of surgery at Columbia University Medical Center, squared off against each other in a debate about whether common femoral artery lesions can be treated with endovascular techniques as opposed to always being treated surgically, but they ended up coming to the same conclusion: Results from current studies show that both treatment modalities are safe and effective in this patient population.

SAN DIEGO — More information is needed regarding how to pretreat patients with dual antiplatelet therapy before PCI, but recent research has provided more evidence as to how to switch from one therapy to another after patients undergo PCI, according to two presentations at TCT 2018.

SAN DIEGO — Localized drug delivery with a micro-infusion device was effective at 24 months in patients with peripheral artery disease undergoing primary atherectomy or primary angioplasty, according to findings presented at TCT 2018.

SAN DIEGO — In a secondary analysis from the SECURE-PCI trial, a periprocedural loading dose of atorvastatin reduced 30-day MACE rates in patients with STEMI undergoing PCI, researchers reported at TCT 2018.

SAN DIEGO — Patients with severe aortic stenosis and high surgical risk who were treated with a transcatheter aortic heart valve had a low risk for mortality and stroke at 1 year, according to data presented at TCT 2018.

Effective management of acute pulmonary embolism begins with a multidisciplinary approach, according to Teresa L. Carman, MD, from the University Hospital Cleveland Medical Center.